Skip to main content
. 2022 Sep 5;2022:4257359. doi: 10.1155/2022/4257359

Figure 2.

Figure 2

Targeting signaling pathways in EC. Schematic representation of the Wnt, Notch, AMPK, MAPK, and Hippo pathways in EC. Novel therapeutics (synthetic and natural) kill EC by targeting these signaling pathways or their components. GSK3β, glycogen synthase kinase 3β; DSH, Disheveled; APC, adenomatous polyposis coli; GGPP, geranylgeranyl pyrophosphate; YAP/TAZ, Yes-associated protein (YAP)/tafazzin (TAZ); JAK/STAT3, Janus kinase/signal transducers and activators of transcription 3; SIRT1, silencing information regulator 2-related enzyme 1 (sirtuin 1); HNF4A, hepatocyte nuclear factor 4 alpha; PGC1A, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPAR-γ, peroxisome proliferator-activated receptor-γ; PI3K-Akt-mTOR pathway, the phosphatidylinositol 3-kinase (PI3K)-serine-threonine kinase (Akt)-mammalian target of rapamycin (mTOR) pathway; p38 MAPK, p38 mitogen-activated protein kinase; pre-SREBP, premature sterol regulatory element-binding protein; M-SREBP, mature sterol regulatory element-binding protein.